Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity

@article{Hahmann2009RhokinaseIA,
  title={Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity},
  author={Christa Hahmann and Thomas Schroeter},
  journal={Cellular and Molecular Life Sciences},
  year={2009},
  volume={67},
  pages={171-177}
}
The emerging critical implications of Rho/Rho-kinase (ROCK) signaling in neurodegenerative diseases, glaucoma, renoprotection, diabetes and cancer have sparked growing interest in the pharmacological potential of ROCK inhibitors beyond their current application in cardiovascular disease. This article discusses the therapeutic benefits of novel ROCK inhibitors in development, and highlights the recent advances in the current understanding of disease-dependent and isoform-specific functions of… 
Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors
TLDR
The asymmetric synthesis of chroman 1, a highly potent ROCK inhibitor, and its analogs is reported, and the inhibitory properties of these compounds for ROCK-II and a selected set of highly homologous kinases are discussed.
Targeting Rho GTPase signaling for cancer therapy.
TLDR
This work will review the strategies currently being used to develop inhibitors of Rho GTPases and downstream signaling kinases and discuss candidate entities.
Rho-kinase: regulation, (dys)function, and inhibition
TLDR
This review focuses on the current status of understanding the multiple functions of Rho-ROCK signaling pathways and various modes of regulation of R Ho-Rock activity, thereby orchestrating a concerted functional response.
An emerging treatment option for glaucoma: Rho kinase inhibitors
TLDR
Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in Phase II and III US Food and Drug Administration trials in the United States, and there are also animal studies indicating that ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glauca surgery.
Rho Kinases in Cardiovascular Physiology and Pathophysiology: The Effect of Fasudil
TLDR
Emerging evidence suggests that selective targeting ROCK isoform based on the disease pathophysiology may represent a novel therapeutic approach for the disease treatment including cardiovascular diseases.
Rho kinase as a therapeutic target in cardiovascular disease.
TLDR
Experimental studies indicate that the RhoA/ROCK pathway in myocardium contributes to cardiac remodeling induced by ischemic injury or persistent hypertrophic stress, thereby leading to cardiac decompensation and heart failure.
Rho-Kinase/ROCK: A Key Regulator of the Cytoskeleton and Cell Polarity
TLDR
This review focuses on the structure, function, and modes of activation and action of Rho‐kinase, which is involved in a wide range of diseases such as vasospasm, pulmonary hypertension, nerve injury, and glaucoma.
Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities
TLDR
This review addresses the various roles the Rho/ROCK pathway plays in angiogenesis, tumour vascular tone and reciprocal feedback from the tumour microenvironment and explores the potential utility of ROCK inhibitors as effective vascular normalising agents.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
Chroman-3-amides as potent Rho kinase inhibitors.
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
TLDR
Indazole substitution played a critical role in decreasing clearance and improving oral bioavailability and a series of dihydropyridones were discovered, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead.
Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors
TLDR
A new compound class of Rho kinase (ROCK) inhibitors containing a 7‐azaindole hinge‐binding scaffold tethered to an aminopyrimidine core is discovered and structure–activity relationships elucidated through biochemical and functional assays.
Effects of SLx-2119, a novel small molecule inhibitor of Rho-associated kinase ROCK (ROK), on growth of human tumor xenografts in nude mice
TLDR
Results suggest that in addition to previously reported inhibition of tumor metastasis, ROCK inhibitors may also directly inhibit growth of primary tumors in human tumor xenograft-bearing mice.
Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor
TLDR
A novel and potent selective Rho-kinase inhibitor with promising antihypertensive activity is identified and characterized and its effects in biochemical, cellular, tissue-based, and in vivo assays are characterized.
Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control
TLDR
The proposed pharmacological blockade of the RhoA/ROCK pathway with either fasudil or simvastatin constitutes a novel approach to the treatment of diabetic nephropathy.
Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho
TLDR
It is found that Rho and its effector, Rho-associated kinase, preferentially regulated the amount of A β42 produced in vitro and that only those NSAIDs effective as Rho inhibitors lowered Aβ42.
Cardiovascular effects of a novel potent and highly selective azaindole‐based inhibitor of Rho‐kinase
TLDR
The pharmacological characterization of a potent, highly selective and orally active ROCK inhibitor, the derivative of a class of azaindoles, azainDole 1(3‐methyl‐1H‐pyrrolo[2,3‐b]pyridin‐4‐yl)oxy]‐phenyl}pyrimidine‐2,4‐diamine is described.
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
TLDR
Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases.
...
1
2
3
4
5
...